Updated Corporate Presentation

1. ONX-1006: Safer Chemotherapy

• Uses proven paclitaxel (PTX) chemotherapy.
• Designed to concentrate PTX in tumors while protecting normal cells.

2. Outstanding Results

• 20% greater tumor reduction than Abraxane at the same weekly PTX dose.
• No Side Effects at the specified tested dose levels.
• Outstanding preclinical safety margin (Slides 5 and 6).

3. Development Goals

• One year or longer of treatment without side effects.
• 90–100% tumor elimination.
• 70% one-year survival rate.

4. Pancreatic Cancer Market Benchmark

RASONQUE (Daraxonrasib) – Revolution Medicines (RVMD)

• FDA Approval: Stage IV pancreatic cancer, August 2026.
• One Drug, $45 Billion: Market cap, October 2026.
• Survival Benefit: ~6.5 months longer vs. chemotherapy.
• One-Year Survival Rate: 53.2%
• Severe Side Effects: 43.6% (Grade ≥3).
• See Slide 11 for the clinical and market benchmark.

5. Near-Term Objective

• Advance ONX-1006 into human clinical evaluation for Stage IV pancreatic cancer.

For investment or strategic partnership opportunities, visit our Investor & Partner page and submit the inquiry form.